NAD+ and NMN are often presented as competing ways to support the same biological pathway, yet they are not interchangeable compounds. NAD+ is a fully formed coenzyme utilised directly in cellular metabolism, whereas NMN is a smaller precursor that the body can convert into NAD+ via its own biosynthetic pathways. [1] This distinction becomes particularly important when comparing products. NMN is most commonly studied as an oral precursor, whereas direct NAD+ is available in forms such as intravenous infusions, injections, and oral or sublingual preparations.
The evidence base for these approaches also differs. Oral NMN has been evaluated in numerous controlled human studies and has been shown to be able to increase NAD+-related biomarkers in the blood. Direct administration of NAD+, particularly via intravenous or injection routes, has significantly less controlled data regarding clinical outcomes in relation to the frequently promoted applications concerning anti-aging and general well-being. [2–5]
A more useful question therefore is not simply whether NAD+ or NMN is „better”, but what evidence exists for each route of administration, what was actually measured in humans, and how closely these results correspond to the goal we are interested in.
NAD+ vs NMN?
NAD+ and NMN are different molecules linked within the same metabolic pathway.
NMN, or nicotinamide mononucleotide, is a precursor that can be converted into NAD+ by enzymes naturally present in the body. Products containing direct NAD+, on the other hand, attempt to deliver the ready-made NAD+ molecule. [1]
These roads are therefore fundamentally different.
In the case of NMN, the simplified process is as follows:
NMN → NAD+
This conversion is catalysed by enzymes known as nicotinamide mononucleotide adenyltransferases, or NMNATs. [1]
Direct NAD+ preparations theoretically bypass the precursor stage because they supply already formed NAD+. However, placing NAD+ in the bloodstream or digestive tract does not automatically mean it is known how much intact NAD+ ultimately reaches various intracellular compartments.
Currently, a greater amount of data from human studies relates to precursors.
Randomised trials have shown that oral NMN can increase blood NAD+ levels. [2,4] By comparison, a 2026 systematic review of NAD+ interventions did not identify any eligible controlled clinical trials of direct intravenous or intramuscular NAD+ administration for anti-ageing or broadly defined wellness applications. [3]
This does not mean that the direct administration of NAD+ has no biological effects.
It does, however, mean that its widespread commercial use currently outstrips the strength of controlled human evidence regarding many of the benefits attributed to it.
How is NMN converted into NAD+ in the body?
NMN is very closely linked to NAD+ in the body’s biosynthetic pathways.
Once it has entered the relevant cellular pathways, NMN can be converted into NAD+ in reactions catalysed by NMNAT enzymes. These enzymes add the remaining adenine-containing component required for the formation of NAD+. [1]
This short biochemical pathway is one of the reasons for the high level of interest in NMN as a precursor to NAD+.
Human studies provide evidence that oral NMN may influence NAD+ metabolism.
In one randomised, multicentre, double-blind, placebo-controlled trial, 80 middle-aged and older healthy individuals received 300, 600 or 900 mg of NMN daily for 60 days. Blood NAD+ concentrations increased in a dose-dependent manner in the NMN-treated groups. [2]
The researchers also noted an improvement in the results of the six-minute walk test in the groups taking higher doses.
However, no significant improvement in insulin sensitivity was observed. [2]
This difference illustrates an important principle in NAD+ research: an increase in an NAD+-related biomarker does not automatically imply the occurrence of all the subsequent physiological effects that might seem likely on the basis of the biochemical mechanisms alone.
A separate study involving healthy Japanese men evaluated a single oral dose of NMN at doses of up to 500 mg. The researchers analysed clinical parameters and nicotinamide metabolites and reported no significant safety concerns during the study. [4]
Taken together, these studies suggest that oral NMN may be involved in NAD+ metabolism in humans.
However, they do not confirm that NMN is a treatment for ageing or any specific disease.
Direct NAD+ versus precursor supply: advantages and limitations
Direct NAD+ in an intravenous infusion, injection or sublingual preparation
The rationale behind the direct administration of NAD+ seems straightforward: rather than supplying a precursor and relying on the body to complete the synthesis of NAD+, the ready-made molecule is administered.
Intravenous administration also bypasses the digestive tract.
This approach has become popular in wellness clinics and centres offering infusion therapies, where NAD+ may be promoted in relation to energy, recovery, cognitive function or anti-ageing.
However, bypassing the gastrointestinal tract should not be equated with a proven improvement in the delivery of NAD+ to cells, nor with better clinical outcomes.
The evidence available remains limited.
A systematic review from 2026 revealed a significantly higher number of human intervention studies involving oral NAD+ precursors than those involving direct intravenous or intramuscular NAD+ in anti-ageing and wellness applications. No eligible controlled clinical outcome trials were identified concerning intravenous or intramuscular NAD+ in these applications. [3]
In another retrospective pilot study based on real-world practice, intravenous NAD+ was compared with intravenous nicotinamide riboside, another NAD+ precursor. In this analysis, intravenous NAD+ was associated with a greater number of gastrointestinal and cardiovascular symptoms. [5]
As this was a retrospective pilot study rather than a randomised controlled trial, it should not be regarded as definitive proof that intravenous NAD+ is less safe than strategies using precursors.
However, it demonstrates why tolerance depending on the route of administration requires appropriate research, rather than assuming that direct administration is inherently better.
Oral NMN
NMN takes a different approach.
Instead of supplying ready-made NAD+, it supplies a naturally occurring intermediate compound that can be incorporated into the body’s own NAD+ biosynthesis pathways.
Its main advantage, from an evidence-based perspective, is that oral NMN has been evaluated in randomised, placebo-controlled trials involving humans. These studies have demonstrated an increase in NAD+-related biomarkers and, overall, good short-term tolerability. [2,4]
However, the evidence becomes less clear-cut when moving from NAD+ biomarkers to actual clinical outcomes.
An increase in NAD+ levels in the blood does not indicate an improvement in cognitive function, a longer lifespan, increased energy, protection against disease or the reversal of the ageing process.
The evidence therefore supports a more limited conclusion: oral NMN may influence NAD+ metabolism in humans, whilst the broader clinical significance of this phenomenon is still being investigated.
A comparison of NAD+ and NMN: absorption, cost and form
| Feature | Direct NAD+ (IV/injection) | Direct NAD+ (sublingual/oral) | NMN (oral) |
|---|---|---|---|
| What does it deliver | Fully formed NAD+ | Fully formed NAD+ | NAD+ precursor |
| Main trail | Direct administration of NAD+ | Direct administration of NAD+ | Conversion to NAD+ by NMNAT |
| Method of administration | Intravenous infusion or injection | Sublingual or oral preparation | Capsule, tablet or powder |
| alimentary canal | Bypassed when given intravenously | It depends on the formulation | Oral absorption, followed by metabolism |
| Controlled human trials | Limited to anti-aging/wellness effects [3] | Limited | Numerous studies involving human participants [2,4] |
| Evidence regarding NAD+ biomarkers | Less well characterised in controlled outcome studies | Limited | An increase in NAD+ levels in the blood has been demonstrated [2] |
| Tolerance data | Limited; retrospective data suggest that the findings depend on the route of administration [5] | Insufficiently characterised | Generally beneficial in short-term studies involving humans [2,4] |
| Typical availability | IV/wellness clinics and centres | The supplements market | The supplements market |
| The complexity of the application | Highest | Lower | Lower |
| Relative cost | Usually high due to the need for administration in a clinical setting | Variable | Usually more accessible |
Cost and availability may vary significantly depending on the country, formulation, supplier and regulatory environment; they should therefore not be regarded as fixed characteristics.
More importantly, neither convenience nor price constitutes proof of biological efficacy.
Can NAD+ and NMN be taken together?
At present, there is insufficient direct data from human studies to determine whether combining direct NAD+ administration with oral NMN offers any additional benefits.
Both approaches ultimately affect the same NAD+ metabolic system.
NMN provides a precursor that can be converted into NAD+, whilst the direct administration of NAD+ provides the coenzyme in its ready-to-use form.
It might therefore seem logical that combining them should have a greater effect.
However, this has not been demonstrated.
Dedicated, controlled trials involving human participants would be needed to determine whether the combination of these interventions results in:
- greater availability of NAD+;
- no significant additional effect;
- altered metabolism;
- different responses in different tissues;
- additional side effects;
- or clinically relevant benefits outweighing each method used separately.
In the absence of such data, describing NAD+ and NMN as a proven synergistic „stack” goes beyond the available evidence.
This is particularly important when NAD+ is administered directly by intravenous infusion or injection, as these routes raise additional issues relating to administration and tolerability which do not arise in the same way with an oral precursor. [5]
What better suits a specific goal: energy, longevity, or concentration?
The response requires, above all, the separation of confirmed biological effects from proposed health benefits.
NAD+ biomarker testing
If the question relates specifically to which approach has stronger controlled human evidence for increasing NAD+-related biomarkers, oral precursors currently have a clearer evidence base.
Human clinical studies show that oral NMN can increase blood NAD+ concentrations. [2,4]
A 2026 systematic review also showed that precursor interventions have a significantly greater number of controlled human trials than direct intravenous or intramuscular NAD+ used for anti-aging and wellness purposes. [3]
This does not mean that NMN provides better clinical outcomes.
It only means that this specific biological effect has been better researched.
Energy and physical performance
NAD+ plays a central role in cellular energy metabolism, providing a strong mechanistic basis for investigating interventions that increase its availability.
Improving NAD+ availability does not necessarily translate into a noticeable increase in energy or physical performance in humans.
Some studies on NMN have noted changes in physical performance outcomes, including the six-minute walk test. However, other metabolic indicators did not consistently improve. [2]
Further research is needed before NAD+ or NMN can be considered proven interventions for increasing physical performance or helping to treat fatigue.
Longevity and ageing
The biology of NAD+ is closely linked to research into ageing, as NAD+ plays a role in mitochondrial metabolism, DNA repair, sirtuin activity and other processes that change with age.
This constitutes a sound scientific basis for research into longevity.
However, this does not mean a proven extension of human life span.
Neither NMN nor direct NAD+ administration have been shown in robust controlled human trials to be methods that extend lifespan or reverse biological ageing.
It is crucial to distinguish between influencing the ageing pathway and achieving a clinically significant anti-ageing effect.
Cognitive functions
NAD+ metabolism is also being studied in neuroscience, as neurons have high metabolic demands and mitochondrial dysfunction is observed in many neurological disorders.
However, the available evidence does not support either NMN or NAD+ directly as effective and proven methods for improving cognitive function.
Claims regarding memory, concentration, neuroprotection or neurological disorders require data relating directly to these outcomes, rather than merely to the fact that NAD+ is involved in brain metabolism.
Direct intravenous or injectable NAD+
The idea that intravenous NAD+ should work better because it is delivered „directly” may seem intuitive, but it has not yet been adequately proven.
Intravenous administration bypasses absorption from the gastrointestinal tract.
This does not automatically mean better delivery of NAD+ into cells, greater tissue exposure, better clinical outcomes, or greater safety.
According to a 2026 systematic review, controlled data on clinical outcomes for intravenous or intramuscular NAD+ in anti-ageing and wellness applications remained particularly limited. [3]
The comparison most consistent with the evidence is therefore not: „NAD+ works and NMN does not” nor „NMN is better than NAD+”.
Currently, oral NMN has stronger controlled human evidence regarding the alteration of NAD+-related biomarkers, whereas direct NAD+ administration has a much more modest base of controlled trials concerning clinical outcomes. It remains unknown whether either approach yields significant long-term benefits for longevity, cognitive function, energy, or disease prevention.
Limitations of current evidence
The most important limitation is the lack of direct randomised trials comparing oral NMN with direct NAD+ administration under equivalent experimental conditions.
The current comparisons are therefore based primarily on separate studies involving different populations, doses, durations of use, routes of administration and endpoints.
Data on the tolerability of intravenous NAD+ are also limited. A study comparing intravenous NAD+ with intravenous NR was retrospective and conducted in real-world practice settings rather than as a randomised controlled trial. The results help to highlight potential tolerability issues, but do not allow for a definitive safety comparison. [5]
Controlled clinical outcome data for direct intravenous or intramuscular NAD+ remain notably sparse. A 2026 systematic review identified no eligible controlled trials evaluating these methods in anti-ageing or wellness applications. [3]
NMN has a stronger human research base regarding increasing blood NAD+ biomarkers, but this should not be equated with proof of broader health benefits. Functional results in studies on NAD+ precursors have been inconsistent, and their long-term clinical significance remains uncertain. [2]
Another limitation is tissue specificity. Changes measured in the blood do not automatically mean equivalent changes in NAD+ in skeletal muscle, brain, liver, heart or other tissues.
Nor have any specific human studies been identified that evaluate the concurrent use of direct NAD+ and oral NMN. Claims regarding additive or synergistic effects therefore remain unconfirmed.
Disclaimer
This article is for educational and scientific-informational purposes only. It does not constitute medical advice, a diagnosis, treatment guidance, dosage instructions, injection or infusion instructions, or a recommendation for the use of NAD+, NMN, NR, or other NAD+-related compounds.
Research into NAD+ metabolism encompasses well-understood biochemical mechanisms, as well as findings from cellular, animal and human studies with varying levels of evidence. An increase in blood levels of NAD+ or its associated metabolites should not be interpreted as evidence of improved longevity, increased energy, improved cognitive function, disease prevention or the reversal of biological ageing.
Direct administration of NAD+, including via intravenous or injection routes, has a limited base of controlled human data for many anti-aging and wellness applications. NMN has stronger data regarding its impact on NAD+-related biomarkers, but its long-term clinical benefits and safety remain incompletely established.
Health decisions regarding NAD+ supplements, intravenous infusions, injections or other interventions should be discussed with a qualified healthcare professional, particularly in the case of pregnant or breastfeeding women, people with existing medical conditions, and those taking prescription medicines.
References
[1] Yoshino, J., Baur, J. A., & Imai, S. (2018). NAD+ intermediates: The biology and therapeutic potential of NMN and NR. Cell Metabolism, 27(3), 513–528. https://doi.org/10.1016/j.cmet.2017.11.002
[2] Yi, L., Maier, A. B., Tao, R., Lin, Z., Vaidya, A., Pendse, S., Thasma, S., Andhalkar, N., Avhad, G., & Kumbhar, V. (2022). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomised, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 45, 29–43. https://doi.org/10.1007/s11357-022-00705-1
[3] Gallagher, C., & Emmanuel, O. O. (2026). NAD+ supplementation for anti-ageing and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews, 116, 103057. https://doi.org/10.1016/j.arr.2026.103057
[4] Irie, J., Inagaki, E., Fujita, M., Nakaya, H., Mitsuishi, M., Yamaguchi, S., Yamashita, K., Shigaki, S., Ono, T., Yukioka, H., Okano, H., Nabeshima, Y., Imai, S., & Yasuda, K. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine Journal, 67(2), 153–160. https://doi.org/10.1507/endocrj.EJ19-0313
[5] Reyna, K., Heinzen, G., Patel, N., Ritter, M., Siojo, A., Legere, H., & Pojednic, R. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): A retrospective tolerability pilot study in a real-world setting. Frontiers in Aging, 7, 1652582. https://doi.org/10.3389/fragi.2026.1652582